Placebo Control

Adam Feuerstein points out - and expresses considerable alarm over - an overlooked clause in the 21 st Century Cures Act: Waive infor...

My recommended reading list -- highlights from the past week: Absolute required reading for anyone who designs protocols or is engaged in...

A quick update on my last post regarding the enormously controversial -- but completely unmentioned -- requirement to publicly report all v...

Not to be confused with the Test Act . (via Luminarium) 4 Democratic members of Congress recently co-sponsored the TEST (Trial and Expe...

Following up on yesterday's post regarding a study of placebo-related information, it seems worthwhile to pause and expand on the diffe...

4 out of 5 non-doctors recommend starting with "regular strength", and titrating up from there... (Photo from inventedbyamother....

In what appears to be, oddly enough, an exclusive announcement to Pharmalot, Pfizer will be discontinuing its much-discussed “Trial in a b...

Two intriguing articles on participation in clinical trials were published this week. Both happen to be about breast cancer, but both touch...

The concept of “unrealistic optimism” among clinical trial participants has gotten a fair bit of press lately, mostly due to a small study ...

The authors of EDICT's white paper , in their executive summary, take a bleak view of the current state of clinical trial accrual: Of cr...